Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2007

Invitrogen Partners with Cytori to Offer Adipose Stem Cell Research Products

  • Invitrogen will offer Cytori Therapeutics’ adipose-derived stem cell-based research products to life science investigators, through a global strategic supply and commercialization agreement. "This product offering provides life science researchers access to an important and validated stem cell population," points out Joydeep Goswami, Ph.D., vp of stem cells and regenerative medicine for Invitrogen.

    "Adipose-derived stem cells represent an attractive cell source from which to conduct regenerative medicine research," Dr. Goswami continues. Marc H. Hedrick, M.D., president for Cytori Therapeutics, notes that, "this relationship will expand the number of therapeutic applications under development with these cells as a means to broaden the opportunities for Cytori to provide stem cell-based therapies."

    Invitrogen's reagents that are used to isolate, characterize, expand, and differentiate stem cells will complement Cytori’s products. "Aligning ourselves with Invitrogen adds an additional partner offering Cytori's adipose stem cells for research purposes," says Dr. Hedrick.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »